While these IO therapeutics are very effective in some patients (the responders), many patients do not derive benefit (non-responders), are at risk for serious side effects from these costly therapies, and may miss opportunities for alternative therapy options. [3 ,4]
Therefore, there is a strong unmet medical need for tests that can guide selection of the appropriate treatment. We are working closely with members of our world-renowned scientific advisory board to further maximize the clinical benefits of this test.
Our goal has always been to help patients and physicians by providing products that provide unprecedented insight and benefit. We will continue to advance this cause by introducing new tests and applications and leveraging our analytical platform.
|Proof of Concept||Classifier Validation||LDT Validation||Commercially Available|
|Dawn™||Immuno-Therapy Response Prediction in MM, NSCLC, and Other Malignancies|
|Glori™||Pelvic Mass Triaging|
|Advanced Adenoma||Pre-malignant Detection, Cancer Prevention|
|Colorectal Cancer||Early Cancer Detection, Colonoscopy Triaging|
|Prostate Cancer||Differentiation Between Indolent and Aggressive Variants|
|Non-Alcoholic SteatoHepatitis (NASH)||Early Detection, and Clinical Decision|
|Hepatocellular Carcinoma (HCC)||Early Detection, and Clinical Decision|
|Nasopharyngeal Carcinoma||Early Detection, and Clinical Decision|
|Renal Cell Carcinoma||Differentiation Between Indolent and Aggresive Variants|
|Pancreas Carcinoma||Early Detection|
|Non Small Cell Lung Carcinoma (NSCLC)||Early Detection|